Ireland for Pharmaceutical & Life Sciences Structuring

Ireland's Pharmaceutical Sector

Ireland is home to 9 of the world's 10 largest pharmaceutical companies and 18 of the top 25 medical device companies. The pharmaceutical and life sciences sector is Ireland's largest export industry, accounting for over €90 billion in annual exports — more than half of Ireland's total goods exports.

Major pharmaceutical companies with substantial Irish operations include:

• Pfizer: Multiple manufacturing sites in Cork and Dublin; Ireland is Pfizer's largest manufacturing centre outside the US
• Johnson & Johnson: European HQ in Dublin; Janssen Sciences manufacturing in Cork
• Novartis: Ringaskiddy manufacturing site (one of the largest pharmaceutical plants in Europe)
• Roche: Clarecastle manufacturing facility
• MSD (Merck): Multiple sites in Cork, Tipperary, and Dublin
• AbbVie: Cork manufacturing and commercial operations
• Amgen: Dun Laoghaire biologics manufacturing
• Bristol-Myers Squibb: Cruiserath biologics campus (investment of over €1.2 billion)
• Eli Lilly: Kinsale manufacturing site
• Sanofi: Waterford and Dublin operations

Why Pharma Chose Ireland

1. The 12.5% Corporate Tax Rate

Pharmaceutical companies' Irish trading profits — from manufacturing, distribution, commercial operations, and actively managed IP licensing — are taxed at 12.5%. Given the high-margin nature of pharmaceutical products (gross margins of 70-90% are common), the difference between Ireland's 12.5% and the typical European rate of 25-30% represents hundreds of millions in annual tax savings for large pharmaceutical groups.

2. Capital Allowances for Intangible Assets (CAIA) — Section 291A

Section 291A of the TCA 1997 allows companies to claim tax depreciation (capital allowances) on the cost of acquiring intangible assets, including:

• Patents and supplementary protection certificates (SPCs)
• Trademarks and brand names
• Copyright (including copyright in software)
• Know-how and trade secrets
• Customer lists and contractual relationships
• Goodwill directly attributable to the IP

The allowance is calculated on a straight-line basis over 15 years — i.e., the company can deduct 1/15th (6.67%) of the IP acquisition cost against its taxable profits each year.

The Impact on Effective Tax Rates

When a pharmaceutical company acquires IP at arm's length and claims CAIA:

• The CAIA deduction reduces taxable profits
• Combined with the 12.5% trading rate, the effective tax rate during the 15-year write-down period can be significantly below 12.5%
• After the write-down period, the effective rate reverts to the headline 12.5%

This mechanism was instrumental in enabling pharmaceutical companies to "onshore" IP to Ireland following the closure of the Double Irish structure. Companies acquired IP from related entities (at arm's length prices, supported by transfer pricing analyses) and claimed CAIA deductions on the acquisition cost.

Cap: The annual CAIA deduction is capped at 80% of the company's trading income attributable to the IP. The remaining 20% is taxed at 12.5%, ensuring a minimum effective rate of approximately 2.5% during the write-down period.

3. The R&D Tax Credit (25%)

Ireland's 25% R&D tax credit (Section 766 TCA 1997) provides a credit on qualifying R&D expenditure:

• Staff costs: Salaries and employment costs of employees engaged in qualifying R&D activities
• Materials and consumables: Directly attributable to R&D
• Overhead costs: Apportioned based on the proportion of staff time dedicated to R&D
• Subcontracted R&D: Up to 15% of total qualifying expenditure may be subcontracted to universities or approved research organisations

The credit is in addition to the full trading deduction of R&D expenditure, creating a combined benefit of approximately 37.5% on qualifying spend.

For pharmaceutical companies, qualifying R&D activities include:

• Drug discovery and development
• Clinical trials (phases I-IV)
• Process development and scale-up for manufacturing
• Biosimilar and generic development
• Medical device development and testing

4. The Knowledge Development Box (6.25%)

Pharmaceutical companies that hold patented IP can apply the Knowledge Development Box to qualifying income at an effective rate of 6.25%. Given that pharmaceutical products are almost universally protected by patents (and often by SPCs that extend patent protection), the KDB is particularly relevant to the pharma sector.

5. Manufacturing Excellence

Ireland has a world-class pharmaceutical manufacturing infrastructure:

• Active Pharmaceutical Ingredient (API) manufacturing — Ireland is one of the largest producers of APIs in the world
• Biologics manufacturing — several billion-euro biologics facilities have been built in Ireland in recent years (Bristol-Myers Squibb's Cruiserath campus, MSD's Swords facility, Amgen's Dun Laoghaire plant)
• Sterile fill-finish — critical for injectables and vaccines
• HPRA oversight — the Health Products Regulatory Authority (HPRA) is Ireland's pharmaceutical regulator, with a strong reputation for quality oversight and alignment with EMA standards

6. Clinical Trial Infrastructure

Ireland offers an efficient environment for clinical trials:

• The Health Research Board (HRB) coordinates clinical research activity
• The HPRA approves clinical trial applications in line with the EU Clinical Trials Regulation (EU 536/2014)
• Ireland's English-speaking population simplifies patient consent and documentation
• A well-educated healthcare workforce supports recruitment and site management

7. EU Market Access

Post-Brexit, Ireland is the only English-speaking EU member state — making it the natural European hub for pharmaceutical companies that require:

• EMA regulatory pathway — Ireland-manufactured products benefit from the EU's centralised marketing authorisation procedure
• Free movement of goods — pharmaceutical products manufactured in Ireland can be distributed across the EU single market without customs barriers or additional regulatory approvals
• Qualified Person (QP) release — Irish-based QPs can certify product batches for EU-wide distribution

Transfer Pricing Considerations

The Irish Revenue Commissioners have significantly strengthened their transfer pricing regime through the Finance Act 2019, which introduced:

• New TP rules aligned with the OECD Transfer Pricing Guidelines (2017 edition)
• Mandatory TP documentation (master file and local file) for companies with annual turnover exceeding €250 million or annual net turnover exceeding €50 million
• Applicability of TP rules to both trading and non-trading transactions

For pharmaceutical groups, the key transfer pricing considerations in Ireland include:

• IP valuations: The arm's length price for IP acquired from related parties must be supported by a robust valuation (discounted cash flow, comparable transactions, or cost-based methods)
• Manufacturing profit allocation: Irish manufacturing entities must be remunerated on an arm's length basis for the functions performed, assets used, and risks assumed
• Commercial and distribution functions: Irish entities managing EMEA commercial operations must be allocated appropriate returns

Key Takeaways

• 9 of the top 10 pharma companies have substantial Irish operations — manufacturing, commercial, and IP management
• The 12.5% trading rate, CAIA (Section 291A), R&D tax credit (25%), and KDB (6.25%) create a layered tax advantage for pharma groups
• CAIA allows IP acquisition costs to be written off over 15 years, reducing effective tax rates well below 12.5% during the write-down period (minimum ~2.5%)
• Ireland's biologics manufacturing infrastructure has received billions in investment, establishing the country as a global centre for biopharmaceutical production
• Post-Brexit, Ireland is the only English-speaking EU jurisdiction with access to the EMA regulatory pathway
• Transfer pricing requirements have been materially strengthened — arm's length pricing of IP transactions and manufacturing returns is critical